Building biology in 3D for cancer drug discovery and precision medicine by decoding patient derived scaffolds (PDS)

Patient-derived scaffolds and analyses of adapting cancer cell lines can monitor malignant properties of a cell-free cancer microenvironment highlighting distinct links between scaffold influences and clinical aggressiveness in cancer. The protein composition of the cell-free cancer microenvironments influencing adapting cancer cells have been defined by quantitative mass spectrometry and results indicate clear clustering of PDS differing in extracellular matrix related proteins as well as immunoregulatory and metabolic regulators. Interestingly both the defined clusters as well as individual imprinted proteins in the cell-free scaffolds are linked to clinical behaviours of the cancer and data from breast cancer and colorectal cancer will be presented. The multitude of proteins imprinted in the cell-free cancer scaffolds representing various tumour biological activities and cell types, supports the importance of the cancer microenvironment in influencing varying disease behaviours. The in vivo identified proteins can be used for improved disease subtyping, cancer drug targeting and importantly to construct optimal synthetic 3D-models that can be used for human-like drug discovery and validation of novel cancer treatments. Data from the first prototypes of human-mimicking synthetic scaffolds will be presented and discussed in relation to other 3D-based growth models available for cancer discovery.

Göran Landberg, M.D., Ph.D.


University of Gothenburg

Göran Landberg has a highly competitive competence in molecular pathology based translational research and has established several national and international centers focusing on molecular pathology and breast cancer and has worked as professor and senior consultant in England and  Sweden. He is currently running a large research group focusing on cancer stem cells and the cancer microenvironment at the Sahlgrenska Cancer Center in Sweden linked to one of the largest hospitals in northern Europe. He has also started two companies focusing on novel diagnostic methods and therapies for breast cancer. Landberg has published more than 190 articles with an H-index of 63 and has supervised 25 Ph.D. students to graduation. The long-term goal within his research activities is to develop novel treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.


Building Biology in 3D for Cancer Drug Discovery and Precision Medicine by Decoding Patient Derived Scaffolds (PDS)
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available